Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…Abstract Number: 0547 • ACR Convergence 2025
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…Abstract Number: 0318 • ACR Convergence 2025
Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
Background/Purpose: Lipoprotein subclasses play diverse roles in health and disease. Although lipoproteins have been implicated in knee osteoarthritis (KOA), the relationship between lipoprotein subclasses and…Abstract Number: 2606 • ACR Convergence 2025
The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases
Background/Purpose: Social media (SM) and Artificial Intelligence (AI) are common sources of health information for patients with chronic diseases. Seeking medical information from unreliable sources…Abstract Number: 2338 • ACR Convergence 2025
Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Background/Purpose: The use of combination biologic and targeted synthetic DMARDs remains controversial due to safety concerns, yet may offer benefit in refractory inflammatory arthritis. This…Abstract Number: 2054 • ACR Convergence 2025
A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) encompass a heterogenous group of autoimmune diseases characterized by inflammation of muscle and other target organs. Muscle biopsy was historically…Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…Abstract Number: 0544 • ACR Convergence 2025
Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
Background/Purpose: Despite a choice of multiple targeted DMARDs, with different modes of action (MoA), a number of patients with axial spondyloarthritis (axSpA) have failed several…Abstract Number: 0306 • ACR Convergence 2025
Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
Background/Purpose: Increased intestinal permeability (IP) is common in chronic inflammatory diseases, and can be measured indirectly (e.g., with blood markers such as lipopolysaccharide, LPS), or…Abstract Number: 2575 • ACR Convergence 2025
Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
Background/Purpose: Women with systemic rheumatic diseases (SRDs), and particularly those on immunosuppressive medications, are at increased risk for serious infections such as influenza and COVID-19.…Abstract Number: 2331 • ACR Convergence 2025
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Background/Purpose: To identify patient characteristics and disease phenotypes associated with coping strategies in axial spondyloarthritis (axSpA), and assess whether coping strategies change over time.Methods: Data…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 38
- Next Page »